Vol 7, No 4 (2016)
Review paper
Published online: 2017-04-07
The WHO 2016 classification of B-cell lymphomas — important changes
Hematologia 2016;7(4):261-272.
Abstract
The revised 2016 World Health Organization (WHO) classification of B-cell lymphomas includes the latest updates both on clinical, biological, pathomorphological and diagnostic criteria along with rapidly developing genetic studies for existing entities. Special attention was paid to the early events in lymphoid neoplasms, focusing on highly aggressive B-cell lymphomas and the impact of newer cytogenetic/molecular studies; particularly for their potential use in targeted therapies. Several new provisional entities were introduced. As in previous editions, the updated WHO 2016 classification of B-cell lymphomas is a platform, which serves to codify changing observations and represents a consensus between hematopathologists, geneticists and clinicians concerning potentially controversial topics. It is also forms the basis for clinical practice guidelines.
Keywords: WHO 2016 classificationB-cell lymphomas
References
- Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H. ed. World Health Organization classification of tumours. IARC, Lyon 2008.
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
- Ganapathi KA, Pittaluga S, Odejide OO, et al. Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica. 2014; 99(9): 1421–1432.
- Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009; 360(7): 659–667.
- Vardi A, Dagklis A, Scarfò L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 2013; 121(22): 4521–4528.
- Morabito F, Mosca L, Cutrona G, et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res. 2013; 19(21): 5890–5900.
- Gibson SE, Swerdlow SH, Ferry JA, et al. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica. 2011; 96(8): 1144–1152.
- Pillai RK, Surti U, Swerdlow SH. Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica. 2013; 98(10): 1571–1580.
- Mamessier E, Song JY, Eberle FC, et al. Early lesions of follicular lymphoma: a genetic perspective. Haematologica. 2014; 99(3): 481–488.
- Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012; 97(2): 270–278.
- Takata K, Tanino M, Ennishi D, et al. Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci. 2014; 105(5): 608–615.
- Perry AM, Warnke RA, Hu Q, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013; 122(22): 3599–3606.
- Petrella T, Maubec E, Cornillet-Lefebvre P, et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol. 2007; 31(12): 1887–1892.
- Louissaint A, Ackerman AM, Dias-Santagata D, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012; 120(12): 2395–2404.
- Giné E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010; 95(9): 1526–1533.
- Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121(8): 1403–1412.
- Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364(24): 2305–2315.
- Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012; 119(14): 3330–3332.
- Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014; 46(1): 8–10.
- Dietrich S, Hüllein J, Hundemer M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012; 366(21): 2038–2040.
- Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367(9): 826–833.
- Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia. 2013; 27(8): 1722–1728.
- Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016; 468(3): 259–275.
- Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014; 123(18): 2791–2796.
- Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012; 122(10): 3416–3423.
- Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012; 26(8): 1895–1898.
- Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013; 121(8): 1394–1402.
- Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013; 110(45): 18250–18255.
- Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009; 113(5): 1053–1061.
- Salaverria I, Philipp C, Oschlies I, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, German High-Grade Lymphoma Study Group, Berlin-Frankfurt-Münster-NHL trial group. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011; 118(1): 139–147.
- Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16(9): 1111–1122.
- Xerri L, Dirnhofer S, Quintanilla-Martinez L, et al. The heterogeneity of follicular lymphomas: from early development to transformation. Virchows Arch. 2016; 468(2): 127–139.
- Swerdlow SH. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 90–99.
- Kluin P. High grade B-cell lymphoma. In: Swerdlow SH. ed. WHO classification of tumors of hematopoietic and lymphoid tissues. World Health Organization classification of tumours. IARC, Lyon .
- Swerdlow SH. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 90–99.
- Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013; 122(26): 4246–4292.
- Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014; 123(23): 3567–3573.
- Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014; 124(10): 1563–1569.
- Dunleavy D, Pittaluga S, Grant N, et al. Gray zone lymphomas: clinical and histological characteristics and treatment with dose-adjusted EPOCH-R. Blood. 2008; 112: 1228.
- Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014; 11(1): 12–23.
- Karube K, Campo E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol. 2015; 52(2): 97–106.
- Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28): 3452–3459.
- Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011; 43(9): 830–837.
- Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012; 44(12): 1321–1325.
- Salaverria I, Martin-Guerrero I, Wagener R, et al. Molecular Mechanisms in Malignant Lymphoma Network Project, Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014; 123(8): 1187–1198.
- Sewastianik T, Prochorec-Sobieszek M, Chapuy B, et al. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim Biophys Acta. 2014; 1846(2): 457–467.
- Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012; 22(2): 167–179.
- Nicolae A, Pittaluga S, Abdullah S, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015; 126(7): 863–872.
- Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010; 34(3): 405–417.
- Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000; 95(4): 1406–1412.
